Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer by Zammit, C et al.
Fibroblast growth factor 8 is expressed at higher levels in lactating
human breast and in breast cancer
C Zammit
1, R Coope
1, JJ Gomm
1, S Shousha
1, CL Johnston
1 and RC Coombes*
,1
1Cancer Research (UK) Laboratories, Department of Cancer Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
Fibroblast growth factor 8 can transform NIH3T3 cells and its expression has been found to be associated with breast and
prostate cancer. Following our ﬁnding that ﬁbroblast growth factor 8 mRNA expression is increased in breast cancer, we have
undertaken an immunohistochemistry study of ﬁbroblast growth factor 8 expression in a series of human breast tissues and
other normal tissues. Our ﬁndings conﬁrm increased expression of ﬁbroblast growth factor 8 in malignant breast tissue but
also show signiﬁcant ﬁbroblast growth factor 8 expression in non-malignant breast epithelial cells. No signiﬁcant difference in
ﬁbroblast growth factor 8 expression was found between different grades of ductal carcinoma, lobular carcinoma and ductal
carcinoma in-situ or cancer of different oestrogen receptor, progesterone receptor or nodal status. The highest levels of
ﬁbroblast growth factor 8 expression were found in lactating breast tissues and ﬁbroblast growth factor 8 was also detected in
human milk. A survey of other normal tissues showed that ﬁbroblast growth factor 8 is expressed in the proliferative cells of
the dermis and epithelial cells in colon, ovary fallopian tube and uterus. Fibroblast growth factor 8 appears to be expressed in
several organs in man and appears to have an importance in lactation.
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The ﬁbroblast growth factors (FGFs) form a family of at least 23
growth regulatory proteins that share 35–50% amino acid
sequence identity. They induce proliferation and differentiation
in a wide range of cells of epithelial, mesodermal and neuroecto-
dermal origin (Basilico and Moscatelli 1992; Tanaka et al, 1992;
Hu et al, 1998; Powers et al, 2000). FGF8 was originally isolated
from the conditioned medium of an androgen dependent mouse
mammary carcinoma line (SC-3) as an androgen induced growth
factor (AIGF) and was later assigned as a member of the ﬁbroblast
growth factor family on the basis of structural similarity (Tanaka et
al, 1992). FGF8 appears to have an important role in embryogen-
esis and is expressed in several areas of the developing mouse and
may play a critical role in gastrulation and the development of the
face, limb and central nervous system (Vogel et al, 1996; Neubuser
et al, 1997; Meyers et al, 1998; Ye et al, 1998; Tucker et al, 1999;
Sun et al, 1999). Little expression of FGF8 has been found in adult
mouse tissues with comparatively low amounts detected only in the
ovaries and testes (MacArthur et al, 1995a; Lorenzi et al, 1995).
We have been interested in assessing the role of ﬁbroblast
growth factors in the normal and malignant human breast.
Previous work has shown that FGF1 and FGF2 are expressed in
the normal breast, implying roles for these growth factors in main-
taining the structure of the normal ducts (Gomm et al, 1991, 1997;
Coope et al, 1997). In breast cancer, there is a decrease in the
amount of FGF1 and FGF2 present in breast tissue (Bansal et al,
1995; Yiangou et al, 1997a). However, in the case of FGF1, there
is evidence for some remaining in a more functionally available
form in breast cancers (Smith et al, 1994; Coope et al, 1997).
FGF7 is found in similar amount in both malignant and non-
malignant breast tissues. It is produced by stromal ﬁbroblasts
and acts via the KGF receptor (FGFR2-IIIb) on epithelial cells
(Bansal et al, 1997). Other studies show no expression of FGF3
and FGF4 in human breast cancers but expression of all other FGFs
in at least a small proportion of breast cancers (Penault-Llorca et
al, 1995). All four of the FGFRs are expressed to some degree in
breast cell lines (McLeskey et al, 1994; Johnston et al, 1995).
Although ampliﬁcation of the fgfr4 gene has been found in 10%
of breast cancers, we have previously shown that equivalent levels
of FGFR-4 are present in the epithelial cells of malignant and
non-malignant breast sections (Jaakkola et al, 1993; Coope et al,
1997). In the case of FGFR-1, signiﬁcant changes in the isoform
of FGFR-1 expressed occur on malignant transformation although
the level of expression appears to stay the same (Coope et al, 1997;
Yiangou et al, 1997b).
One group of splice variants of the FGFR family involves the use
of alternative exons encoding the carboxyl-terminal half of the
third immunoglobulin domain. This form of splice variation
occurs for FGFR-1, FGFR-2 and FGFR-3 so that IIIb and IIIc forms
of these receptors have very different ligand binding properties
(Miki et al, 1992; Werner et al, 1992; Chellaiah et al, 1994). These
two isoforms appear to be expressed in a mutually exclusive fash-
ion, with cells of mesenchymal origin expressing IIIc variants of
FGFR2 and FGFR3 whereas epithelial cells express the IIIb isoform
(Pekonen et al, 1993; Savagner et al, 1994). The interaction of
several splice variants of FGF8 with high afﬁnity receptors has been
investigated and FGF8b has been shown to have the widest recep-
tor binding properties, activating FGFR2-IIIc as well as FGFR3-IIIc
and FGFR4 (MacArthur et al, 1995b).
FGF8 was identiﬁed as an oncogene on the basis of overexpres-
sion of FGF8 in NIH3T3 cells leading to focus formation, growth
in soft agar and tumour formation in nude mice (Kouhara et al,
1994). FGF8 was subsequently found to act as a proto-oncogene
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(Kapoun and Shackleford, 1997). Transgenic mice in which FGF8
was expressed under an MMTV promoter developed breast cancer
over a period of months implying that FGF8 may be able to
promote breast cancer in mice (Daphna-Iken et al, 1998).
Previous work has shown that FGF8 is expressed by prostate and
breast cancer cell lines (Tanaka et al, 1995; Schmitt et al, 1996).
Some investigators have demonstrated an involvement in malignant
prostate disease since FGF8 was detected in prostatic cancers, but
not in benign prostatic hypertrophy (Leung et al, 1996). Further
studies indicated that FGF8 over-expression was an indicator of
poor prognosis (Dorkin et al, 1999). However, other groups have
failed to ﬁnd this correlation between tumour grade and level of
FGF8 expression (Tanaka et al, 1998; Wang et al, 1999). We have
previously studied the expression of FGF8 mRNA in a series of
malignant and non-malignant breast tissue and found that FGF8
transcripts are more frequently detected in malignant tumours
and at a higher level than benign tissue (Marsh et al, 1999). In this
study, we have extended our investigations into the role of FGF8 in
the human breast by using antibodies against FGF8 to detect its
presence in human breast samples. We ﬁnd low levels of FGF8 in
normal breast epithelial cells and the level of staining appears to
be increased in some breast cancers. However, the highest levels
of FGF8 expression were found in lactating mammary glands, indi-
cating a possible role for this growth factor in lactation.
We have also investigated the expression of FGF8 in normal
human tissues using immunohistochemistry in order to clarify
whether FGF8 also acts as a normal regulator of cell activity.
Our ﬁndings indicate that FGF8 is widely expressed in the normal
adult and is likely to be important in the regulation of mature
tissues as well as in their development.
MATERIALS AND METHODS
Tissues
Parafﬁn blocks of 124 human breast tissues were used in this study.
The details of the 85 breast cancer patients are shown in Table 1.
Eight cases of invasive ductal carcinoma occurred in lactating
tissue. The remaining tissues were from ﬁve cases of ﬁbroadenoma,
17 normal tissues from reduction mammoplasty tissue, 11 normal
lactational tissues and six cases of DCIS. Of the 85 carcinoma
tissues, 54 contained elements of adjacent normal tissue.
Parafﬁn sections of normal human tissues were also analysed
and included skin, rectum, duodenum, ovary, cervix, endometrium
and fallopian tube.
Materials
Humanmilkwasobtainedfromthemilkbankatthepost-nataldepart-
ment of Queen Charlotte’s Hospital/London. FGF8 protein and anti-
FGF8monoclonalantibodywereobtainedfromR&Dsystems(Abing-
don, UK). All other chemicals were from Sigma (Poole, UK).
Immunohistochemistry using a monoclonal antibody
against FGF8
Parafﬁn sections were dewaxed in xylene and hydrated through
graded alcohol and heated under pressure in 0.01 M citrate buffer
pH 6.0 to reveal the antigen. Endogenous avidin and biotin were
blocked using the avidin/biotin blocking kit (Vector). Non-speciﬁc
binding was blocked with 10% horse serum and 5% BSA in PBS
for 30 min. The sections were then treated for 16 h at 48C with
1 mgm l
71 anti-FGF8 monoclonal antibody (R&D) in PBS. Control
sections were incubated with 1 mgm l
71 non-immune mouse IgG
(Sigma). Samples were washed three times in PBS and incubated
with biotinylated anti-mouse IgG diluted in PBS with 10% human
serum for 30 min at room temperature. After washing three times
in PBS, the sections were incubated in ABC reagent (Vector
Laboratories) for 1 h at room temperature. After washing three
times in PBS, staining was visualised by addition of a 0.05% solu-
tion of 3,3'-diaminobenzidine (DAB) in PBS containing 001%
hydrogen peroxide. Sections were then counterstained with Gill’s
haematoxylin, dehydrated, cleared and mounted.
Blocking experiments were performed by incubating the anti-
FGF8 monoclonal antibody at 1 mgm l
71 with 100 mgm l
71 of
recombinant FGF8 (R&D) for 16 h at 48C. The antibody was then
used to stain sections using the protocol described above.
Scoring of staining
The level of staining was recorded as 0, +, ++ or +++ with 0 indi-
cating no staining and +++ maximal staining. Scoring was checked
by a histopathologist, experienced in breast disease who was
blinded to the preliminary scoring results. Comparison of staining
levels in oestrogen receptor positive and negative tumours or
progesterone receptor positive and negative tumours was done
using the Mann Whitney U-test. These receptor analysis were done
routinely with primary tissue analysis at time of surgery by the
histopathology laboratory at Charing Cross Hospital, London,
using conventional techniques.
Western blot detection of FGF8
Samples containing recombinant FGF or protein precipitated from
milk were run on a 12% polyacrylamide gel and then transferred
onto nitrocellulose for 16 h at 200 mA. The nitrocellulose was
blocked by incubating with 3% casein in PBS with 0.1% Tween
20 for 1 h. The blot was probed with monoclonal anti-FGF8
(R&D) for 1 h and was washed three times in PBS. Incubation with
an anti-mouse IgG-horseradish peroxidase conjugate (Sigma) was
followed by extensive washes in PBS with 0.1% washes in PBS with
0.1% Tween 20 and development with ECL reagents (Amersham).
Milk protein samples were prepared by centrifuging milk at 1000 g
for 10 min to separate fat from milk. The semi-skimmed milk was
ﬁltered through a Microcon 100 to eliminate proteins of a molecu-
lar weight higher than 100 kDa. The milk solution was acidiﬁed to
pH 4.6 using 1 M HCl to precipitate casein. This was centrifuged at
400 g for 30 min and the supernatant collected and neutralised to
pH 7.6 with NaOH. The resulting proteins were used in Western
analysis.
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Characteristic No. of patients
Totals 85
Age range (years) 32–81
Median age 57
Menopausal status Pre/peri 31
Post 50
Unknown 4
Nodal status Positive 21
Negative 18
Unknown 46
Histological type Invasive ductal 75
Invasive lobular 10
Histological grading Grade I 5
Grade II 35
Grade III 40
Unknown 5
Oestrogen receptor Positive 49
Negative 20
Unknown 16
Progesterone receptor Positive 38
Negative 31
Unknown 16
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Speciﬁcity of the monoclonal antibody against FGF8
The speciﬁcity of the antibody to be used in immunohistochemis-
try was tested for its cross-reactivity against members of the FGF
family by Western blotting. Equal amounts of recombinant
FGF1, FGF2, FGF7, FGF8 and FGF9 were run on a 12% polyacry-
lamide gel. After transfer to nitrocellulose, the blot was probed
using the monoclonal antibody against FGF8. No cross-reactivity
with FGF 1, 2, 7 or 9 was seen (Figure 1).
Expression of FGF8 in human breast tissues
We have previously reported that FGF8 mRNA is expressed at a
higher level in breast cancer cells than in normal breast epithelial
cells (Marsh et al, 1999). Following these observations, we have
used a monoclonal antibody against FGF8 in immunohistochemis-
try to assess the expression and distribution of FGF8 in a series of
malignant and non-malignant human breast tissues. Details of the
breast cancer patients studied are shown in Table 1 and in addi-
tion, 17 normal reduction mammoplasty tissues, ﬁve cases of
ﬁbroadenoma and 11 normal lactating breast tissues were analysed.
Immunostaining of human breast sections from invasive ductal
carcinoma (Figure 2A,B), invasive lobular carcinoma (Figure
2C,D) and DCIS (Figure 2E,F) showed expression of FGF8 in
epithelial cells but not of adjacent stromal elements (Figure
2A,C,E). FGF8 was not found in the nuclei of cells and gave a
diffuse cytoplasmic staining pattern. The staining appeared to be
speciﬁc since pre-incubation of anti-FGF8 with excess recombinant
FGF8, blocked the staining (Figure 2D) and non-immune mouse
IgG at the same concentration gave negative staining (Figure 2B,F).
FGF8 immunostaining could also be detected in non-malignant
breast tissues. In cases of reduction mammoplasty tissue, cytoplas-
mic FGF8 staining was seen in epithelial cells but not in
myoepithelial cells or in stromal elements (Figure 3A). Fibroadeno-
ma tissues also showed cytoplasmic FGF8 immunostaining in the
epithelial cells (Figure 3C). In sections where normal elements of
breast tissues could be seen adjacent to invasive carcinoma, higher
levels of FGF8 staining were consistently seen in carcinoma
elements compared to normal elements (Figure 3E,F). The intensity
of FGF8 immuno-reactivity was graded as 0, +, ++ or +++ and a
score was given to the tissues analysed.
A comparison of the level of FGF8 immuno-reactivity in ﬁbroa-
denoma, normal breast tissue from reduction mammoplasty and
lactational breast tissue (Figure 4A); DCIS, lobular breast cancer
tissue and different grades of invasive ductal carcinoma is shown
(Figure 4B). In general, we found an increase in FGF8 expression
in malignant breast tissues compared to non-malignant. Hence
comparatively low levels of FGF immunoreactivity were found in
normal breast tissue from reduction mammoplasty tissue with
the majority of tissues registering as + and ++. Fibroadenoma
tissues also showed similar low levels of FGF8 expression as normal
breast tissue. DCIS, lobular carcinoma and ductal carcinoma tissues
more commonly registered as ++ and +++. We observed no signif-
icant difference in FGF8 expression between invasive lobular and
invasive ductal carcinoma. No signiﬁcant difference in the level
of FGF8 immunoreactivity was seen in invasive ductal carcinomas
of histological grades II and III. The Grade I breast carcinoma
specimens showed similar low expression of FGF8 as normal breast
tissues but statistical comparative analysis with higher tumour
grades was not possible as numbers were small. No signiﬁcant
difference in FGF8 expression was seen in cancers with different
oestrogen receptor status (P=0.5), progesterone receptor status
(P=0.0534) or nodal status (P=0.138).
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Figure 1 Western blots showing the speciﬁcity of the anti-FGF8 anti-
body. One hundred ng of FGF1 (lane 1), FGF2 (lane 2), FGF7 (lane 3),
FGF9 (lane 4) and FGF8 (lane 5) were run on a 15% polyacrylamide gel
and transferred onto nitrocellulose ﬁlters. These were probed with anti-
FGF8 monoclonal antibody.
A B
C D
E F
Figure 2 Expression of FGF8 in human breast cancer tissue. Parafﬁn sec-
tions of invasive ductal carcinoma (A,B), invasive lobular carcinoma (C,D)
and ductal carcinoma in situ (DCIS) (E,F), were analysed by immunohisto-
chemistry using an antibody against FGF-8 (A,C,E) or the equivalent con-
centration of non-immune mouse IgG (B,F). (D) Shows absence of anti-
FGF8 staining after pre-incubation with 100-fold excess of recombinant
FGF8. (Original magniﬁcation A–D, 6400; E, F, 6200).
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A series of sections from lactating breasts were stained for FGF8
and all showed levels of FGF8 expression higher than any of the
normal or malignant breast sections. Again cytoplasmic staining
of epithelial cells was seen with myoepithelial cells and stromal
components being negative (Figure 5). Protein was isolated from
samples of human milk and Western blot analysis was used to
assess whether FGF8 was present. Five samples of milk analysed
all contained FGF8 (Figure 6).
FGF8 expression in other tissues
Previous reports concerning FGF8 expression in adult mouse
tissues showed only a small amount of FGF8 expression in ovaries
and testes (Lorenzi et al, 1995). To see whether this is a true reﬂec-
tion of FGF8 expression in normal human tissues, an
immunohistochemical study was carried out. FGF8 immunoreac-
tivity was present within the epidermal layer of the skin (Figure
7G,I). The greatest levels of FGF8 staining was found towards
the bottom of the epidermal layer containing dividing cells rather
than in the more differentiated upper layers. Sections of skin
containing sweat glands showed high FGF8 staining of the sweat
glands (Figure 7I).
FGF8 expression was also detected within the human bowel.
Sections of rectum showed immunoreactivity at the base of
goblet cells and in surface epithelial cells (Figure 7J,K). Inter-
stitial lymphocytes and plasma cells were stained positive. In
sections of duodenum, columnar absorptive cells showed positive
cytoplasmic staining mainly at the base but also in more super-
ﬁcial parts of some cells (Figure 7E). Intestinal Goblet cells and
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Figure 3 Expression of FGF8 in non-malignant human breast tissue. Par-
afﬁn sections of normal breast tissue from reduction mammoplasty tissue
(A,B), ﬁbroadenoma (C,D) and parafﬁn sections containing elements of
both invasive ductal carcinoma and adjacent normal breast tissues (E,F),
were analysed by immunohistochemistry using an antibody against FGF8
(A,C,E,F) or the equivalent concentration of non-immune mouse IgG
(B,D). (Original magniﬁcation A–B, 6400; C–F 6200).
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Figure 4 Histograms showing the level of FGF8 immunoreactivity in ma-
lignant and non-malignant breast tissue. Tissues were scored as +, ++ or
+++ for FGF8 staining. (A) Shows percentages of patients with each level
of staining in: 1=Fibroadenoma; 2=Normal breast tissue (reducton mam-
moplasty); 3=Lactating breast tissue. (B) Shows FGF8 staining patterns in
Invasive Ductal Carcinoma Grade 1, 2 and 3; DCIS and Lobular carcinoma.
Figure 5 FGF8 staining in lactating mammary gland. Parafﬁn sections of
lactating mammary gland tissue were stained with an antibody against
FGF8 (A,C) or with the equivalent concentration of non-immune mouse
IgG (B,D). (Original magniﬁcation A, B, 6200; C, D, 6400).
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the cells.
In the ecto-cervix, the stratiﬁed squamous layer showed faint
staining but the keratin layer was clear. More immunoreactivity
was found in the endocervix with columnar cells lining glands
showing positive staining (Figure 7D). FGF8 expression was also
seen in the columnar epithelial cells of the fallopian tube (Figure
7C). Within the ovary, high levels of FGF8 were seen in the Corpus
Luteum. In the endometrium, glands showed positive staining
(Figure 7A). The endometrial stroma was negative, however the
myometrium showed positive staining.
DISCUSSION
FGF8 is of potential interest in breast biology since it was ﬁrst
isolated from a mouse mammary carcinoma cell line and its
expression is regulated by steroid hormones; in particular dihy-
droxytestosterone (Tanaka et al, 1992; Payson et al, 1996). FGF8
is able to function as an oncogene, causing transformation of
NIH3T3 cells and inducing breast tumours in transgenic mice
expressing FGF8 under an MMTV promoter (Kouhara et al,
1994; Daphna-Iken et al, 1998). FGF8 expression appears to be
associated with human carcinoma of the prostate since higher
levels of FGF8 were detected in malignant prostate disease (Leung
et al, 1996; Tanaka et al, 1998). However, another group found
FGF8 expressed in benign prostatic hypertrophy as well as prostate
cancer (Wang et al, 1999). FGF8 expression has also been shown in
a proportion of breast cancers and normal breast tissues (Tanaka et
al, 1998; Marsh et al, 1999). Although immunohistochemical
studies have been carried out showing a correlation between the
grade of prostate cancers and the amount of FGF8 expression, such
extensive studies have not previously been carried out using human
breast tissue. Our studies show that although FGF8 expression
appears to be slightly higher in malignant breast disease than in
normal breast tissue, FGF8 is expressed in normal epithelial cells
and in fact the highest level of FGF8 expression were found in
lactating mammary gland.
The results of the staining are consistent with previously
published reports. mRNA encoding FGF8 mRNA has been found
expressed in the epithelial cells of breast cancer using in situ hybri-
disation and we ﬁnd a similar expression pattern in the epithelial
component of normal and malignant breast tissue (Marsh et al,
1999). It has been reported that FGF8 mRNA is present in a
proportion of both malignant and non-malignant breast tissues
(Wu et al, 1997; Tanaka et al, 1998). Our ﬁndings show that the
majority of breast epithelial cells contain considerable levels of
FGF8 protein.
The staining pattern observed indicates that FGF8 has a cyto-
plasmic or membrane bound localisation but is not seen in the
nucleus of epithelial cells. This is in contrast with several other
members of the FGF family. FGF 1, 2 and 3 have been detected
in the cell nucleus (Cao et al, 1993; Presta et al, 1993; Antoine et
al, 1997). Eight different splice variants of FGF8 are possible in
the mouse but in man due to a stop codon only four of these
forms are possible (Crossley and Martin, 1995; Gemel et al,
1996). Previous studies have indicated that FGF8b is the predomi-
nant form in breast tissue (Marsh et al, 1999) and that FGF8b has
been shown to have the greatest transforming ability (MacArthur et
al, 1995b). The monoclonal anti-FGF8 antibody used in this study
(R&D Systems) was produced from a mouse hybridoma in which
the immunogen was an E. coli-derived recombinant mouse ﬁbro-
blast growth factor 8b.
Transgenic mice overexpressing FGF8 under an MMTV promo-
ter have been reported to produce lobular carcinoma of the breast
(Daphna-Iken et al, 1998). We therefore compared the levels of
FGF8 staining in groups of invasive ductal and invasive lobular
carcinoma. We failed to detect any difference in FGF8 expression
in the two groups, suggesting that the causal relationship implied
in mice may not be important in humans. A comparison of
FGF8 expression in different histological grades of ductal carcino-
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Figure 7 Immunostaining of different normal human tissues. Shown are
section of endometrium (A,B); fallopian tube (C); endocervix (D); duode-
num (E,F); skin (G,H); skin with sweat glands (I); rectum (J,K and L). (Ori-
ginal magniﬁcation A–H, J,L, 6200; I,K, 6200.
22 kDa_
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Figure 6 Western blots demonstrating the presence of FGF8 in human
breast milk. Proteins from human milk samples were run on a 12% polya-
crylamide gel, transferred onto nitrocellulose and probed using the mono-
clonal antibody against FGF8. Lanes A–E contain milk proteins and lane F
contains 100 ng of recombinant FGF8.
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of breast tumour. This is in contrast to a prostate cancer report in
which higher levels of FGF8 were found in less differentiated
cancers (Leung et al, 1996; Tanaka et al, 1998; Dorkin et al,
1999). It is known that FGF8 expression is regulated by androgens
(Tanaka et al, 1992). We see no evidence of higher FGF8 expres-
sion correlating with loss of oestrogen or progesterone receptors.
Previous reports have shown that dihydoxytestesterone but neither
oestrogen nor progesterone was able to upregulate FGF8 expression
(Payson et al, 1996). In view of these ﬁndings, it is not surprising
that FGF8 expression fails to correlate with ER or PR status.
The highest levels of FGF8 expression were detected in lactating
mammary gland, strongly implicating FGF8 as having an important
role in lactation. A large number of hormones and related peptides
are present in milk and colostrum; insulin, epidermal growth factor
(EGF), insulin-like growth factor I (IGF-I) and cortisol are abun-
dantly present (Xu, 1996). FGF8 has been implicated in
embryological development especially gastrulation suggesting roles
in brain, limb and facial development (Ohuchi et al, 2000). FGF8
has also been implicated in morphogenic outgrowth of the hepatic
endoderm (Jung et al, 1999). However in the early post natal peri-
od the gastrointestinal tract is still in a process of development and
maturation which seem to be under the inﬂuence of milk ingested
(Xu, 1996). With the presence of high quantities of FGF8 in
human milk, FGF8 along with other growth/hormonal factors
may be implicated in this process.
We also used immunohistochemistry to determine the expression
of FGF8 in normal adult tissues. By this method, we were able to
detect FGF8 expression in the epithelial cells of many of the tissues
examined. The widespread expression pattern suggests that FGF8
has physiological roles in adult tissue as well as in development.
Previous studies have used Northern blotting and in situ hybridi-
sation to detect FGF8 expression. High levels of FGF8 mRNA were
found during development in the mouse whereas in the adult mouse
a little expression was found in ovary and testis (Lorenzi et al, 1995).
Our results conﬁrm expression of FGF8 in the ovary, however more
widespread expression was apparent. This could indicate that the
immunohistochemical method used is more sensitive or it could
reﬂect a difference between the two species. Our ﬁnding of FGF8
expression in normal breast tissue is in agreement with previous
reports studying mRNA and protein levels (Tanaka et al, 1998; Marsh
et al, 1999). Since we have not included foetal tissue in this study, it is
possible that higher levels are present in development.
Other members of the FGF family are expressed in adult tissues
and in many cases the activity of such growth factors is tightly
regulated to prevent inappropriate cell responses. In the case of
FGF1 and FGF2, release is the point of regulation since these
growth factors lack a signal peptide and are therefore not secreted
by the classical pathway. Release of these growth factors is possible
but appears to be regulated by binding of integrins to extracellular
matrix components and other factors such as oestrogen stimulation
(Mousa et al, 1999).
Since FGF8 contains a signal peptide, its regulation is more
likely to follow the model of FGF7. FGF7 binds to only one FGF
receptors, the IIIb isoform of FGFR-2. Since ephithelial cells exclu-
sively express FGFR2-IIIb and FGF7 is secreted by ﬁbroblasts, FGF7
is likely to act in a paracrine fashion (Bansal et al, 1997). A similar
situation may occur in the case of FGF8, which is expressed prin-
cipally in epithelial cells with very little expression seen in stromal
tissues in this study and in other reports (Tanaka et al, 1998;
Marsh et al, 1999). Its receptor binding properties have been
reported previously and the highest afﬁnity receptors are FGFR2-
IIIc, FGFR3-IIIc and FGFR4 (Ornitz et al, 1996). Both FGFR2-IIIC
and FGFR3-IIIc receptors are expressed predominantly in ﬁbro-
blasts (Yan et al, 1993; Scotet and Houssaint, 1995). Again this
raises the likelihood of FGF8 operating through a paracrine inter-
action, being released by epithelial cells and acting on surrounding
ﬁbroblasts. FGFR4 is another receptor for FGF8.We have
previously shown that FGFR4 is present in epithelial cells of
normal (including lactating breast) and malignant breast tissue
(Coope et al, 1997), therefore an autocrine loop of FGF8/FGFR4
is also possible.
Detailed immunohistochemical staining for FGFRs has been
carried out on a range of normal human tissues and show wide-
spread expression of this family of proteins in the normal adult
(Hughes, 1997). Within the skin, high levels of FGFR2 were found
in dermal ﬁbroblasts. FGF8 expression is found in the basal level of
the skin, providing a potential paracrine interaction for FGF8. A
high level of FGFR3 expression was found in the cervix including
its presence in stromal ﬁbroblasts. The presence of FGF8 in the
epithelial cells of the cervix suggests a similar paracrine interaction
with the stroma. In the duodenum, expression of FGFR2 and
FGFR3 was found in the muscularis mucosae giving potential
interactions for the FGF8 released by columnar epithelial cells.
High level of FGFR-3 were also detected in the colon. No expres-
sion of FGFR-2 or FGFR-3 was found in the ovary.
The widespread expression of FGF8 in normal tissues implicates
this growth factor as having a physiological role in the adult as well
as during development. Because of its production by epithelial cells
and the presence of its receptors on ﬁbroblasts, it probably has a
paracrine mode of action in skin, cervix, duodenum and rectum.
Its function in the endometrium and ovary is less clear since
FGF8 appears to be localised towards the apical surface of epithelial
cells in these tissues.
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